P13K is a protein kinase, and a P13K inhibitor is a substance that inhibits the activity of this enzyme. The pathway where P13K is located has been found to be mutated and abnormally activated in many types of cancers, and is considered to be closely related to the survival and proliferation of tumor cells, so it has become a reliable therapeutic target for many types of cancers, and scientists have accordingly prepared P13K inhibitors to study their value in treating cancers. However, according to the latest research results, it is found that the clinical therapeutic effect of P13K inhibitors is not good, the survival rate of patients is not obvious, and when used alone, it will also promote the metastasis and proliferation of tumor cells to a certain extent, which will lead to further deterioration of the patient’s condition. It is recommended that patients receive standardized treatment under the guidance of a doctor, do not blindly use drugs, so as not to delay the condition.